title: Chronic constipation and treatment options (Review).
abstract: Chronic constipation (CC) is a highly prevalent heterogeneous disorder. Although CC is not known to be associated with the development of serious disease or with excess mortality, it considerably reduces the patients quality of life. In addition, it represents an economic burden to patients and society. The majority of patients with CC successfully manage the disorder by dietary management and the use of laxatives. Patients with functional CC (slow‑transit and non‑slow transit constipation) do not respond to laxatives and are a small fraction of the total population complaining of constipation. Regardless of the low number of these patients, the intractability of their symptoms causes psychological and social stress and greatly impairs their quality of life. Furthermore, these patients consume a disproportionate quantity of medical resources. It appears that these patients have a disturbance in the serotonin transmission system, which results in a cascade of alterations in a number of gut neuroendocrine hormones/transmitters. The effect of prucalopride, a serotonin receptor agonist, in this category of patients appears to be not only a pharmacological prokinetic action, but also a correction of a pre‑existing disturbance. Linaclotide, a member of the guanylin peptide family, binds to the ligand‑binding region of guanylate cyclase‑C on the luminal surface of gastrointestinal epithelia resulting in increased fluid secretion. This drug has also been found to be effective for the treatment of functional CC. In addition, biofeedback and sacral nerve stimulation are effective in the treatment of CC caused by pelvic floor disorders.
authors.affiliation: Section for Gastroenterology, Department of Medicine, Stord Hospital, Stord 5416, Norway.
authors.forename: Magdy
authors.initials: M
authors.lastname: El-Salhy
authors.forename: Rune
authors.initials: R
authors.lastname: Svensen
authors.forename: Jan Gunnar
authors.initials: JG
authors.lastname: Hatlebakk
authors.forename: Odd-Helge
authors.initials: OH
authors.lastname: Gilja
authors.forename: Trygve
authors.initials: T
authors.lastname: Hausken
mesh_terms: D002908:Chronic Disease; D003248:Constipation / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D054368:Laxatives / Q000627:therapeutic use*; D009490:Neurosecretory Systems / Q000378:metabolism
chemical_list: D054368:Laxatives